CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock TÜBINGEN, Germany/BOSTON, USA

CureVac CEO Alexander

Zehnder Acquires Common Shares of Company Stock

T BINGEN, Germany/BOSTON, USA

- January 17, 2024 - CureVac N.V. (Nasdaq: CVAC) ("CureVac"), a global biopharmaceutical company

developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that

its Chief Executive Officer, Alexander Zehnder, recently purchased 50,000 common shares of CureVac stock.

from our Phase 2 COVID-19 vaccine development program in collaboration with GSK have again underlined the enormous potential of our proprietary

mRNA technology," said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. "We are building a strong clinical pipeline

for prophylactic vaccines and are increasing our footprint in cancer immunotherapy. My purchase shows my continued commitment to the company

and confidence in the value of our differentiated mRNA technology, which puts CureVac at the forefront of a scientific revolution that

holds immense potential for improving the health of people and patients."

CureVac (Nasdaq: CVAC) is a global biopharmaceutical

company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing

this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized

mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July

2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based

on CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19

vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline

across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has

its headquarters in T bingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium,

Switzerland and the U.S. Further information can be found at www.curevac.com.

Curevac Media Contact

Schicker, Associate Director Communications

CureVac Investor Relations Contact

Fakih, Vice President Corporate Communications and Investor Relations

Forward-Looking Statements CureVac

This press release contains statements that constitute

"forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995,

including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V.

and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services

GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or

future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the

company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market

growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend,"

"believe," "estimate," "plan," "seek," "project," or "expect,"

"may," "will," "would," "could," "potential," "intend," or "should,"

the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions

and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's

performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties

and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide

financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing,

expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products,

ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures

from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's

business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,

ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings,

different judicial outcomes or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are

cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause

its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release

are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements

or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required

For further information, please reference the

company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting

EDGAR on the SEC website at www.sec.gov.